UK markets closed

Infinity Pharmaceuticals, Inc. (INFI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.5900-0.0423 (-6.69%)
At close: 04:00PM EDT
0.6000 +0.01 (+1.69%)
After hours: 07:50PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.6323
Open0.6112
Bid0.5800 x 800
Ask0.6000 x 4000
Day's range0.5613 - 0.6300
52-week range0.4600 - 3.8900
Volume602,907
Avg. volume850,862
Market cap52.602M
Beta (5Y monthly)2.18
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Infinity Pharmaceuticals to Participate in Upcoming H.C. Wainwright Global Investment Conference

    CAMBRIDGE, Mass., May 17, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the upcoming H.C. Wainwright Global Investment Conference May 23-25, 2022.

  • Business Wire

    Infinity Pharmaceuticals Reports First Quarter 2022 Financial Results

    CAMBRIDGE, Mass., May 03, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) ("Infinity" or the "Company"), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced its first quarter 2022 financial results and provided a corporate update.

  • Business Wire

    Infinity Pharmaceuticals Announces the Date of Its First Quarter 2022 Financial Results Conference Call and Webcast

    CAMBRIDGE, Mass., April 26, 2022--Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, will host a conference call on Tuesday, May 3rd, 2022, at 4:30 pm ET to report its financial results for the first quarter of 2022.